



State of California-Health and Human Services Agency  
**Department of Health Services**

**SANDRA SHEWRY**  
*Director*



**ARNOLD SCHWARZENEGGER**  
Governor

October 31, 2005

CHDP Provider Information Notice No.: 05-15

**TO:** ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP)  
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

**SUBJECT:** ADDITION OF BOOSTER TETANUS, DIPHTHERIA, ACELLULAR  
PERTUSSIS VACCINE (TDAP), AS A CHDP BENEFIT, REPORTING  
CODES, REIMBURSEMENT FOR VACCINE ADMINISTRATION, AND  
UPDATED CHDP VACCINE BENEFIT AND REIMBURSEMENT TABLE

The purpose of this Provider Information Notice (PIN) is to inform you that the new Booster Tetanus, Diphtheria, Acellular Pertussis Vaccine (Tdap), has been added as a CHDP program benefit.

This Information Notice also provides background information on the vaccine, the new CHDP administration codes, and the provider reimbursement rates for vaccine administration. An updated CHDP vaccine benefit and reimbursement table is enclosed that includes the addition of this new vaccine.

### **Background Information**

The Advisory Committee on Immunization Practices (ACIP) recently recommended newly licensed single-dose Tdap to help reduce the number of cases of pertussis among adolescents. ACIP has recommended adolescents (11-18 years) be given Tdap in place of adult tetanus-diphtheria (Td) booster, and adolescents who have already been vaccinated with Td are encouraged to receive a dose of Tdap to further protect against the pertussis. A 5-year interval between Td and Tdap is encouraged to reduce the risk of local or systemic reactions, but intervals shorter than 5 years can be used when appropriate. The benefits of protection from pertussis generally outweigh the risk of local or systemic reactions in settings with increased risk from pertussis (e.g., pertussis outbreaks and close contact with an infant aged <6 months).

Reported cases of pertussis, a highly contagious respiratory tract infection caused by *Bordetella pertussis*, have been increasing dramatically over the past few years, with cases reported to the Centers for Disease Control and Prevention (CDC) at a 40-year high. The most striking numbers are for adolescents and adults, who experience declining protective immunity over time. Immunity against pertussis wanes five to ten years after the last childhood vaccination. Health-care resources, including physician visits and inpatient hospital days, are consumed by adolescents and adults diagnosed with pertussis. The large reservoir of pertussis creates a risk of transmission, particularly to vulnerable infants. In a study supported by the CDC, nearly 50% of all identified infant pertussis sources were parents.

The Food and Drug Administration (FDA) has approved two Tdap vaccines: Boostrix® manufactured by GlaxoSmithKline and Adacel™ produced by Sanofi Pasteur. Boostrix® is currently licensed for persons 10 to 18 years old, while the Adacel™ is indicated for persons age 11 through 64 years.

#### **Tdap as a CHDP Program Benefit**

Effective August 31, 2005, CHDP will reimburse providers for the administration fee of Tdap to CHDP eligible children, 10 years through 18 years 11 months; the vaccine will be provided at no charge by the VFC Program for these children. The CHDP vaccine code is 72 and has the reimbursement rate of \$9.00 for the administration fee. Tdap is not available for purchase.

Booster Tetanus, Diphtheria, Acellular Pertussis (Tdap)	72	VFC	10 years thru 18 years 11 months	\$9.00
---	----	-----	-------------------------------------	--------

These changes will be reflected in the Vaccine Codes and Rates Table found in the rates max CHDP section of the CHDP Provider Manual.

#### **Reminder:**

All CHDP program providers actively involved with immunized children must participate in the VFC Program, which provides vaccines at no cost to the provider for eligible children up to eighteen years eleven months. The CHDP Program reimburses only the immunization administration fee for VFC covered vaccines.

**Billing Instructions for Tdap**

Please use the following instructions for billing for Tdap. Refer to the CHDP Provider Manual for additional information.

- Enter the CHDP Code number, 72, and Tdap on a blank line, under the immunization section of the PM 160 Confidential Screening/Billing Report.
- Enter a check mark in only one of the Immunization Outcome Columns (A or B) of the PM 160, as appropriate.
- Enter the administration fee in the Fees Column (Note: fees do not apply on the "Information Only" PM 160).
- If you have administered Tdap on or after August 31, 2005, and prior to this notice, you are entitled to reimbursement for the administration of this vaccine. Please submit a PM 160 for the \$9.00 administration fee if you have not been previously reimbursed for the vaccine by any source.

**CHDP Vaccine Benefits and Reimbursement Table**

An updated CHDP Vaccine Benefit and Reimbursement Table is enclosed. The table includes the Tdap code and reimbursement rate. Also enclosed is a copy of the letter you previously received from VFC program that includes more specific information on the use of Tdap.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about CHDP vaccine benefits or other CHDP issues, please contact your local CHDP program office.

**Original signed by Marian Dalsey, M.D., M.P.H.**

Marian Dalsey, M.D., M.P.H., Acting Chief  
Children's Medical Services Branch

Enclosures